PolarCool (POLAR) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Achieved a breakthrough three-year league agreement with Czech Extraliga worth 2.5 MSEK, starting 2025/2026.
Expanded presence in American football and rugby with new contracts, including Hamburg Sea Devils and USA Perpignan.
Strengthened financial position by raising 6.76 MSEK through exercised options, with a 78% subscription rate.
Enhanced sales and marketing organization, including hiring a European sales chief and launching a new website.
Ongoing regulatory efforts in the US and Canada, with preparations for broader launches upon approval.
Financial highlights
Net sales for Q1 2025 reached 0.5 MSEK, up from 0.4 MSEK year-over-year.
Operating loss widened to -3.8 MSEK from -2.2 MSEK year-over-year, mainly due to one-time investments in sales and marketing.
Cash and cash equivalents at period end were 9.9 MSEK, up from 0.2 MSEK year-over-year.
Equity at period end was 15.1 MSEK, with a solid equity ratio of 83%.
Personnel and external costs increased due to organizational expansion and digital marketing initiatives.
Outlook and guidance
Main focus for 2025 is achieving profitability through increased sales, especially in Europe.
With current cost structure, 150 rented systems are estimated to cover the company’s cost base.
Expansion efforts continue in Australia, South Africa, and preparations for US and Canada launches in H2 2025.
Ongoing clinical studies and regulatory filings to support market acceptance and future growth.
Latest events from PolarCool
- 28% sales growth in Q4 and new funding support expansion and North American launch plans.POLAR
Q4 202526 Feb 2026 - Regulatory advances and new sports contracts offset Q3 sales dip, with North America launch ahead.POLAR
Q3 202527 Nov 2025 - Secured major league contracts and advanced regulatory approvals, fueling strong sales growth.POLAR
Q2 202528 Aug 2025 - Q3 net sales up 74% year-over-year; US FDA application submitted, targeting 2025 profitability.POLAR
Q3 202413 Jun 2025 - Q2 sales up 45%, new capital secured, and market expansion in sports and geographies.POLAR
Q2 202413 Jun 2025 - Q4 sales up 69%, cash bolstered, and US launch targeted for late 2025.POLAR
Q4 20245 Jun 2025